


Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously presented) A compound of formula I:



wherein:

R¹ and **R^{1'}** are each independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl and cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or **R¹** and **R^{1'}** taken together with the carbon atom to which they are attached form a 3-8 membered saturated or unsaturated ring that optionally contains 1 or 2 heteroatoms;

s is 0 or 1;

U is O, **NR¹¹**, S, SO₂, SO₂**NR¹¹**, CO-O or CO-**NR¹¹**; wherein **R¹¹** is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or **R²** and **R¹¹** taken together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms;

R² is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, Ar-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halogen, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-

cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl, cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, -NO₂, NR¹⁰R^{10'}-C₁₋₆-alk(en/yn)yl, NR¹⁰R^{10'}-C₃₋₈-cycloalk(en)yl and NR¹⁰R^{10'}-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; wherein:

R¹⁰ and R^{10'} are each independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl and cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or

R¹⁰ and R^{10'} taken together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms;

with the proviso that when R² is NO₂, halogen or cyano, then s is 0; and

with the proviso that when R² is a hydrogen atom or acyl and s is 1, then U is NR¹¹, O or S;

the group -(U)_s-R² is linked to position 4 or 6 of the indole or indoline;

q is 0 or 1;

Z is O or S;

X is CO or SO₂; with the proviso that q is 0 when X is SO₂;

R³ is selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, heterocycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, Ar-heterocycloalk(en)yl, Ar-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, Ar-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, C₁₋₆-alk(en/yn)yl-oxy-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl-oxy-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yl-oxy-C₃₋₈-cycloalk(en)yl, C₁₋₆-alk(en/yn)yl-oxy-heterocycloalk(en)yl, Ar-oxy-C₁₋₆-alk(en/yn)yl, Ar-C₁₋₆-alk(en/yn)yl-oxy-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yl-oxy-carbonyl-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl-oxy-carbonyl-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-

alk(en/yn)loxy-carbonyl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-heterocycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, hydroxy-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-heterocycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl-Ar, halo-C₃₋₈-cycloalk(en)yl-Ar, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl-Ar, halo-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl-Ar, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, cyano-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, acyl-C₁₋₆-alk(en/yn)yl, acyl-C₃₋₈-cycloalk(en)yl, acyl-heterocycloalk(en)yl, acyl-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, acyl-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, -NR¹²R^{12'}, optionally substituted NR¹²R^{12'}-C₁₋₆-alk(en/yn)yl, optionally substituted NR¹²R^{12'}-C₃₋₈-cycloalk(en)yl, and optionally substituted NR¹²R^{12'}-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; wherein:

R¹² and R^{12'} are each independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, Ar-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl and cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or







R¹² and R^{12'} taken together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; wherein:

the optional substituent on an Ar or Ar-containing group of R¹² and R^{12'} is independently selected from the group consisting of hydroxy, halogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)loxy, C₃₋₈-alk(en/yn)loxy, acyl, nitro, cyano, -CO-NH-C₁₋₆-alk(en/yn)yl, -CO-N(C₁₋₆-alk(en/yn)yl)₂, -NH₂, -NH-C₁₋₆-alk(en/yn)yl, -N(C₁₋₆-alk(en/yn)yl)₂, -S-C₁₋₆-alk(en/yn)yl, -SO₂-C₁₋₆-alk(en/yn)yl, -SO₂N(C₁₋₆-alk(en/yn)yl)₂ and SO₂NH-C₁₋₆-alk(en/yn)yl;


with the proviso that when R^3 is $NR^{12}R^{12'}$, then q is 0;

and

Y represents a group of formula II, III, IV, V, VI, XXX or XXXI:



or



wherein:

W is O or S;

T is N, NH or O;

L is N, C or CH;

a is 0, 1, 2 or 3;

b is 0, 1, 2, 3 or 4;

c is 0 or 1;

d is 0, 1, 2 or 3;

e is 0, 1 or 2;

f is 0, 1, 2, 3, 4 or 5;

g is 0, 1, 2, 3 or 4;

h is 0, 1, 2 or 3;

j is 0, 1, 2 or 3; with the proviso that when **T** is a nitrogen atom, then **j** is 0, 1, 2 or 3; and
when **T** is NH or an oxygen atom then **j** is 0, 1 or 2;

k is 0, 1, 2, 3 or 4; and

each **R⁵** is independently selected from the group consisting of a C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-thio, Ar-oxy, acyl, C₁₋₆-alk(en/yn)yl-oxy, C₃₋₈-cycloalk(en)yl-oxy, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl-oxy, halogen, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, -CO-NR⁶R^{6'}, cyano, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl, cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, -NR⁷R^{7'}, -S-R⁸ and -SO₂R⁸; or two adjacent **R⁵** groups taken together with the aromatic group to which they are attached form a 4-8 membered ring that optionally contains one or two heteroatoms; wherein:

R⁶ and **R^{6'}** are each independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl and Ar;

R⁷ and **R^{7'}** are each independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and acyl;

and

R⁸ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and -NR⁹R^{9'}; wherein:

R⁹ and **R^{9'}** are each independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; provided that when **R⁸** is -NR⁹R^{9'}; then **R⁵** is not -S-R⁸;

or salts thereof;

with the proviso that the compound of formula I is not:

N-[1-(phenylmethyl)-1H-indol-5-yl]-Methanesulfonamide;

N-[1-[(4-fluorophenyl)methyl]-1H-indol-5-yl]-Methanesulfonamide;

N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-Methanesulfonamide;

N-[1-(phenylmethyl)-1H-indol-5-yl]-N'-4-quinolinyl-Urea;

N-[1-(phenylmethyl)-1H-indol-5-yl]-N'-4-quinolinyl-Urea; or

1-(1-benzyl-5-indoliny)-3-phenyl-Urea;

or salts thereof.

2. (Original) A compound according to Claim 1, wherein at least one of R^1 or $R^{1'}$ is a hydrogen atom.
3. (Previously presented) A compound according to claim 2, wherein both R^1 and $R^{1'}$ are hydrogen atoms.
4. (Previously presented) A compound according to claim 1, wherein s is 0.
5. (Previously presented) A compound according to claim 1, wherein s is 1.
6. (Previously presented) A compound according to claim 1, wherein R^2 is a hydrogen atom.
7. (Previously presented) A compound according claim 1, wherein R^2 is NO_2 or a halogen atom.
8. (Previously presented) A compound according to claim 1, wherein U is NR^{11} .
9. (Previously presented) A compound according to claim 8, wherein R^{11} is a hydrogen atom.
10. (Previously presented) A compound according to claim 1, wherein X is CO .
11. (Previously presented) A compound according to claim 1, wherein X is SO_2 .
12. (Previously presented) A compound according to claim 1, wherein q is 0.
13. (Previously presented) A compound according to claim 1, wherein q is 1.
14. (Previously presented) A compound according to claim 13, wherein Z is an oxygen atom.
15. (Previously presented) A compound according to claim 1, wherein R^3 is selected from the group consisting of C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, Ar, Ar- C_{1-6} -alk(en/yn)yl, Ar-oxy- C_{1-6} -alk(en/yn)yl, Ar- C_{1-6} -alk(en/yn)yl-oxy- C_{1-6} -alk(en/yn)yl and $-NR^{12}R^{12'}$; wherein R^{12} and $R^{12'}$ are as previously defined; and with the proviso that when R^3 is $NR^{12}R^{12'}$, then q is 0.

16. (Previously presented) A compound according to claim 15, wherein R^3 is $NR^{12}R^{12'}$, q is 0 and R^{12} and $R^{12'}$ are each independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, Ar and Ar- C_{1-6} -alk(en/yn)yl; or R^{12} and $R^{12'}$ taken together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms.
17. (Previously presented) A compound according to claim 1, wherein Y is of formula II, III, V, XXX, or XXXI.
18. (Previously presented) A compound according to claim 17, wherein Y is of formula II or III and W is a sulphur atom.
19. (Previously presented) A compound according to claim 17, wherein Y is of formula XXX and T is a nitrogen atom or an oxygen atom.
20. (Previously presented) A compound according to claim 17, wherein Y is of formula XXXI and L is C or CH.
21. (Previously presented) A compound according to claim 1, wherein each R^5 is independently selected from the group consisting of C_{1-6} -alk(en/yn)yl, Ar, Ar-thio, Ar-oxy, halogen and halo- C_{1-6} -alk(en/yn)yl; or two adjacent R^5 taken together with the aromatic group to which they are attached form a 4-8 membered ring that optionally contains one or two heteroatoms.
22. (Previously presented) A compound selected from the group consisting of:
 - N-[4-Chloro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
 - N-[4-Chloro-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
 - [1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid propyl ester;
 - N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-C-phenyl-methanesulfonamide;
 - 4-Fluoro-N-[1-(4-fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-benzamide;
 - N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
 - N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-thiophen-2-ylacetamide;
 - N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

3-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-1,1-diisopropylurea;
Morpholine-4-carboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide;
Pyrrolidine-1-carboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide;
[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid 2-benzyloxyethyl ester;
3-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-1-methyl-1-propylurea;
[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid tert-butyl ester;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-C-phenylmethanesulfonamide;
Butane-1-sulfonic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-4-fluorobenzamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-phenoxyacetamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;
Cyclopentanecarboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-thiophen-2-ylacetamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-isonicotinamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-4-dimethylaminobenzamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-6-trifluoromethylnicotinamide;
1-tert-Butyl-3-[1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-urea;
1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-ethylurea;

1-Benzyl-3-[1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-urea;
1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-phenethylurea;
1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-thiophen-2-ylurea;
1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-thiophen-3-ylurea;
[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid propyl ester;
2,2-Dimethyl-N-[6-nitro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-propionamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide;
2-(4-Fluorophenyl)-N-[6-nitro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
N-[1-(5-Chlorothiophen-2-ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
N-[6-Amino-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide;
N-[6-Amino-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide;
N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
N-[6-Amino-1-(4-fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
N-[6-Amino-1-(3-fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;
N-[6-Bromo-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[6-Bromo-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(4-Chlorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-[1-(4-Isopropylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(3-Fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(6-Chlorobenzo[1,3]dioxol-5-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(2-Chloro-5-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-[5-(4-Chlorophenoxy)-1,3-dimethyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(6-p-tolyloxy-pyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-[1-[6-(4-Chlorophenylsulfanyl)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-[6-(4-Cyanophenoxy)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(6-trifluoromethylpyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

3,3-Dimethyl-N-[1-(3-methyl-benzo[b]thiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-[1-(6-Fluoro-4H-benzo[1,3]dioxin-8-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(6-phenoxy-pyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

3,3-Dimethyl-N-[1-(3-methyl-5-phenyl-isoxazol-4-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-(1-Benzo[b]thiophen-2-ylmethyl-2,3-dihydro-1H-indol-5-yl)-3,3-dimethylbutyramide;
N-{1-[1-(4-Fluorophenyl)-5-methyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-3,3-dimethylbutyramide;
3,3-Dimethyl-N-[1-(5-methylthiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;
3,3-Dimethyl-N-[1-(4-pyrrol-1-yl-benzyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;
N-[1-(4-Chlorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
2-(4-Fluorophenyl)-N-[1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;
2-(4-Fluorophenyl)-N-[1-(4-isopropylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;
2-(4-Fluorophenyl)-N-[1-(3-fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;
N-[1-(6-Chlorobenzo[1,3]dioxol-5-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
N-[1-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
N-[1-(2-Chloro-5-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
N-{1-[5-(4-Chlorophenoxy)-1,3-dimethyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-2-(4-fluorophenyl)-acetamide;
N-{1-[6-(4-Cyanophenoxy)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-2-(4-fluorophenyl)-acetamide;
2-(4-Fluorophenyl)-N-[1-(3-methyl-benzo[b]thiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;
N-[1-(6-Fluoro-4H-benzo[1,3]dioxin-8-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;
2-(4-Fluorophenyl)-N-[1-(6-phenoxy-pyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;
N-(1-Benzo[b]thiophen-2-ylmethyl-2,3-dihydro-1H-indol-5-yl)-2-(4-fluorophenyl)-acetamide;


2-(4-Fluorophenyl)-N-[1-[1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl]-acetamide;

2-(4-Fluorophenyl)-N-[1-(5-methylthiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-acetamide; and

2-(4-Fluorophenyl)-N-[1-(4-pyrrol-1-yl-benzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide; or
 a pharmaceutically acceptable salt thereof.

23. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable carriers or diluents.

24. (Withdrawn-currently amended) A method of increasing ion flow in a potassium channel of a mammal, comprising administering to said mammal a compound of formula I



wherein

the dotted line represents an optional bond;

R¹ and **R^{1'}** are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl and cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl;
 or

R¹ and **R^{1'}** together with the carbon atom to which they are attached form a 3-8 membered saturated or unsaturated ring which optionally contains 1 or 2 heteroatoms;

s is 0 or 1;

U is O, NR^{11} , S, SO_2 , $\text{SO}_2\text{NR}^{11}$, CO-O or CO- NR^{11} ; wherein R^{11} is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^2 and R^{11} together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms;

R^2 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar, Ar- C_{1-6} -alk(en/yn)yl, Ar- C_{3-8} -cycloalk(en)yl, Ar- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, acyl, hydroxy- C_{1-6} -alk(en/yn)yl, hydroxy- C_{3-8} -cycloalk(en)yl, hydroxy- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, halogen, halo- C_{1-6} -alk(en/yn)yl, halo- C_{3-8} -cycloalk(en)yl, halo- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, cyano, cyano- C_{1-6} -alk(en/yn)yl, cyano- C_{3-8} -cycloalk(en)yl, cyano- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, $-\text{NO}_2$, $\text{NR}^{10}\text{R}^{10'}$ - C_{1-6} -alk(en/yn)yl, $\text{NR}^{10}\text{R}^{10'}$ - C_{3-8} -cycloalk(en)yl and $\text{NR}^{10}\text{R}^{10'}$ - C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; wherein

R^{10} and $\text{R}^{10'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl, hydroxy- C_{3-8} -cycloalk(en)yl, hydroxy- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{3-8} -cycloalk(en)yl, halo- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, cyano- C_{3-8} -cycloalk(en)yl and cyano- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, or

R^{10} and $\text{R}^{10'}$ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms;

with the proviso that when R^2 is NO_2 , halogen or cyano then **s** is 0; and

with the proviso that when R^2 is a hydrogen atom or acyl and **s** is 1 then **U** is NR^{11} , O or S;

wherein the group $-(\text{U})_s-\text{R}^2$ is linked to position 4 or 6 of the indole or indoline;

q is 0 or 1;

Z is O or S;

X is CO or SO_2 ; with the proviso that **q** is 0 when **X** is SO_2 ;

R³ is selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, heterocycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, Ar-heterocycloalk(en)yl, Ar-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, Ar-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, C₁₋₆-alk(en/yn)yl-oxy-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl-oxy-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yl-oxy-C₃₋₈-cycloalk(en)yl, C₁₋₆-alk(en/yn)yl-oxy-heterocycloalk(en)yl, Ar-oxy-C₁₋₆-alk(en/yn)yl, Ar-C₁₋₆-alk(en/yn)yl-oxy-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yl-oxy-carbonyl-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl-oxy-carbonyl-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl-oxy-carbonyl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-heterocycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, hydroxy-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-heterocycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl-Ar, halo-C₃₋₈-cycloalk(en)yl-Ar, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl-Ar, halo-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl-Ar, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, cyano-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl, acyl-C₁₋₆-alk(en/yn)yl, acyl-C₃₋₈-cycloalk(en)yl, acyl-heterocycloalk(en)yl, acyl-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, acyl-C₁₋₆-alk(en/yn)yl-heterocycloalk(en)yl and -NR¹²R^{12'}, optionally substituted NR¹²R^{12'}-C₁₋₆-alk(en/yn)yl, optionally substituted NR¹²R^{12'}-C₃₋₈-cycloalk(en)yl, optionally substituted NR¹²R^{12'}-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; wherein:

R¹² and **R**^{12'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, Ar-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl and cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, or


R¹² and **R**^{12'} together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms; wherein:

the optional substituent on an Ar or Ar-containing group of R^{12} and $R^{12'}$ is independently selected from the group consisting of hydroxy, halogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yl, C_{3-8} -alk(en/yn)yl, acyl, nitro, cyano, $-CO-NH-C_{1-6}$ -alk(en/yn)yl, $-CO-N(C_{1-6}-alk(en/yn)yl)_2$, $-NH_2$, $-NH-C_{1-6}$ -alk(en/yn)yl, $-N(C_{1-6}-alk(en/yn)yl)_2$, $-S-C_{1-6}$ -alk(en/yn)yl, $-SO_2-C_{1-6}$ -alk(en/yn)yl, $-SO_2N(C_{1-6}-alk(en/yn)yl)_2$ and SO_2NH-C_{1-6} -alk(en/yn)yl;

with the proviso that when R^3 is $NR^{12}R^{12'}$ then q is 0;

and

Y represents a group of formula II, III, IV, V, VI, XXX or XXXI:



W is O or S;

T is N, NH or O;

L is N, C or CH;

a is 0, 1, 2 or 3;

b is 0, 1, 2, 3 or 4;

c is 0 or 1;

d is 0, 1, 2 or 3;

e is 0, 1 or 2;

f is 0, 1, 2, 3, 4 or 5;

g is 0, 1, 2, 3 or 4;

h is 0, 1, 2 or 3;

j is 0, 1, 2 or 3; with the proviso that when **T** is a nitrogen atom then **j** is 0, 1, 2 or 3; and when **T** is NH or an oxygen atom then **j** is 0, 1 or 2;

k is 0, 1, 2, 3 or 4; and

each **R**⁵ is independently selected from the group consisting of a C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-thio, Ar-oxy, acyl, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl, halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, -CO-NR⁶R^{6'}, cyano, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl, cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, -NR⁷R^{7'}, -S-R⁸ and -SO₂R⁸, or

two adjacent **R**⁵ together with the aromatic group to which they are attached form a 4-8 membered ring which optionally contains one or two heteroatoms;

R⁶ and **R**^{6'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl and Ar;

R⁷ and **R**^{7'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and acyl;

and

R^8 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar and $-NR^9R^{9'}$; wherein R^9 and $R^{9'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; provided that when R^8 is $-NR^9R^{9'}$ then R^5 is not $-S-R^8$; or salts thereof.

25. (Withdrawn) The method of claim 24 wherein administration of said compound is for the prevention, treatment or inhibition of a disorder or condition being responsive to an increased ion flow in a potassium channel.
26. (Withdrawn) The method of claim 25, wherein said disorder or disease is a seizure disorder.
27. (Withdrawn) The method of claim 25, wherein the disorder or condition is selected from the group consisting of neuropathic and migraine pain disorders.
28. (Withdrawn) The method of claim 25, wherein the disorder or condition is an anxiety disorder.
29. (Withdrawn) The method of claim 25, wherein the disorder or condition is a neurodegenerative disorder.
30. (Withdrawn) The method of claim 25, wherein the disorder or condition is a neuronal hyperexcitation state.
31. (Withdrawn) The method of claim 24, wherein the mammal is a human.
32. (Withdrawn) The method of claim 25, wherein the disorder or condition is a disorder or condition of the central nervous system.
33. (Withdrawn) The method of claim 26, wherein the seizure disorder is selected from the group consisting of convulsions, epilepsy and status epilepticus.
34. (Withdrawn) The method of claim 27, wherein the neuropathic or migraine pain disorder is selected from the group consisting of allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.
35. (Withdrawn) The method of claim 28, wherein the anxiety disorder is selected from the group consisting of anxiety, generalized anxiety disorder, panic anxiety, obsessive

compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, specific phobias, anxiety disorder due to general medical condition and substance-induced anxiety disorder.

36. (Withdrawn) The method of claim 29, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy and other infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld-Jakob disease, Parkinson's disease and trauma-induced neurodegenerations.
37. (Withdrawn) The method of claim 30, wherein the neuronal hyperexcitation state is due to medicament withdrawal or intoxication.